SCHEMBL2090296

SCHEMBL2090296

COCc1nnnn1-c1ccc(Cl)cc1

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.61
CYP1A2 P05177 1/20 0.52
CYP2C19 P33261 1/20 0.52
LMNA P02545 4/20 0.51
NPSR1 Q6W5P4 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
MAPT P10636 1/20 0.51
PKM P14618 2/20 0.49
HTT P42858 1/20 0.49
NLRP3 Q96P20 1/20 0.49
GAA P10253 2/20 0.48
IDO1 P14902 1/20 0.48
HSD17B10 Q99714 1/20 0.46
NOTUM Q6P988 1/20 0.45
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2090294 0.84 ALDH1A1 (0.65) ALDH1A1CYP1A2CYP2C19LMNANPSR1
SCHEMBL2095302 0.83 PKM (0.69) ALDH1A1LMNANPSR1L3MBTL1MAPT
SCHEMBL14438050 0.81 ALDH1A1 (0.57) ALDH1A1CYP1A2CYP2C19LMNANPSR1
SCHEMBL2090301 0.80 ALDH1A1 (0.47) ALDH1A1CYP1A2CYP2C19LMNANPSR1
SCHEMBL25250647 0.80 ALDH1A1 (0.72) ALDH1A1CYP1A2CYP2C19LMNANPSR1
SCHEMBL25218290 0.78 CYP1A2 (0.60) ALDH1A1CYP1A2CYP2C19LMNANPSR1
SCHEMBL5546774 0.78 CYP1A2 (0.56) ALDH1A1CYP1A2CYP2C19LMNANPSR1
SCHEMBL2094445 0.78 PRMT1 (0.59) ALDH1A1CYP1A2CYP2C19LMNANPSR1
SCHEMBL14438051 0.76 ALDH1A1 (0.52) ALDH1A1CYP1A2CYP2C19LMNANPSR1
SCHEMBL6002885 0.75 CYP1A2 (0.53) ALDH1A1CYP1A2CYP2C19LMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 ALDH1A1 412/4885CYP1A2 420/4885CYP2C19 1894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.